Harvard Bioscience targets $22.5M–$24.5M Q4 revenue as backlog reaches two-year high, expanding product rollouts and distribution [Seeking Alpha]
Harvard Bioscience, Inc. (HBIO)
Last harvard bioscience, inc. earnings: 2/26 07:15 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.harvardbioscience.com
Company Research
Source: Seeking Alpha
John Duke, President and CEO, reported operational progress and improvements across key areas, stating the company delivered revenue of $20.6 million, which was at the high end of guidance and a slight sequential increase in Quick Insights Harvard Bioscience delivered revenue at the high end of guidance with expanded gross margin, showed positive operating cash flow, and guided for higher Q4 revenue and margin. Order growth and backlog have improved, supporting a positive outlook. Key risks include potential NIH funding delays, a prolonged U.S. government shutdown, and macro uncertainties, with management incorporating these into the lower end of its guidance. New product launches (Incub8), expanded distribution (Fisher Scientific), and increased adoption of high-value telemetry products are driving demand, backlog, and improved financial execution. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
HBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HBIO alerts
High impacting Harvard Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
HBIO
News
- Harvard Bioscience (NASDAQ:HBIO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Harvard Bioscience (NASDAQ:HBIO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Harvard Bioscience (NASDAQ:HBIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Harvard Bioscience (NASDAQ:HBIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Analysts Have Been Trimming Their Harvard Bioscience, Inc. (NASDAQ:HBIO) Price Target After Its Latest Report [Yahoo! Finance]Yahoo! Finance
HBIO
Earnings
- 5/12/25 - Beat
HBIO
Sec Filings
- 11/6/25 - Form 10-Q
- 11/6/25 - Form 8-K
- 11/3/25 - Form SCHEDULE
- HBIO's page on the SEC website